HOME 2019-09-10T17:12:18+00:00

Over a million Americans have Parkinson’s disease (PD) or related disorders such as progressive supranuclear palsy (PSP).  These diseases are characterized by relentlessly worsening motor and cognitive function, caused by degeneration of nerve cells in the brain.  No currently available medication slows or arrests disease progression.  Even symptomatic treatments show declining usefulness in advanced PD and are often ineffective in PSP.  There is an urgent and unmet need for effective treatments for these diseases.

Our work is focused on understanding the mechanisms underlying neurodegeneration in PD and PSP, as an essential step towards developing effective treatments.   Our current projects focus on the roles of the proteins alpha-synuclein and tau in the populations of brain neurons that selectively degenerate in these diseases.  To understand how accumulation of alpha-synuclein and tau causes neurodegeneration, we use a variety of different experimental models and approaches, including engineered viral vectors that alter gene expression in the rodent brain, and transgenic zebrafish that can be analyzed by intravital microscopy, electrophysiology, genetics and biochemistry.  We are also exploring unbiased phenotype-based chemical modifier screens in zebrafish models for drug discovery.  The ultimate goal of this work is to develop treatments that prevent the progression of PD and PSP.


09/20/2019  Ed to present work on drug discovery for PSP at the 4th ZPPM Conference in Toronto.
09/18/2019  Ed to chair opening session of 3rd Z-Brain workshop in Toronto.
09/16/2019  Ed to present work on alpha-synuclein in Parkinson’s disease at 2019 Shanghai Symposium for Medicine in the 21st Century.
09/16/2019  Darius to receive Dean’s Summer Research program Merit Award for his work on automated phenotypic analysis for drug discovery.
07/30/2019  Juhi admitted to the MD program at Rutgers New Jersey Medical School!
02/05/2019  Alya’s paper on long-term alpha-synuclein knockdown in the adult substantia nigra published in Neurobiology of Disease.
01/23/2019  Collaborative paper with Gross Lab on retinal pigment epithelium regeneration published in PLOS Genetics.